Oncology

Latest News

Analyzed by birth cohort, the authors found each successive birth cohort had a 7.7% decline in SCLC rates. | Image credit: shidlovski
Decline in SCLC Incidence Expected to Accelerate Through 2050

June 29th 2025

The incidence of small cell lung cancer (SCLC) is projected to drop by 5.9% each year through 2050.

While elevated NLR previously served as a marker of aggressive disease and poor prognosis in SCLC, its prognostic relevance appears to diminish in the context of immunotherapy-based treatment regimens. | Image credit: Crystal light - stock.adobe.com
Challenging the Prognostic Role of NLR in SCLC in the Era of Immunotherapy

June 27th 2025

Gender rights | Image Credit: © Nadzeya-stock.adobe.com
Culture Key to Data Collection of Sexual Orientation and Gender Identity in Cancer Care

June 23rd 2025

AJMC Q&A with Coral Omene, MD, PhD | Background image credit: ipopba - stock.adobe.com
Addressing Cancer Care Challenges for Patients, and Ensuring Equity: Coral Omene, MD, PhD

June 22nd 2025

Patients with SCLC in the tarlatamab group had significantly longer overall survival, with a median of 13.6 months vs 8.3 months in the chemotherapy group. | Image credit: mi_viri - stock.adobe.com
Tarlatamab Improves SCLC Outcomes After Platinum Chemotherapy

June 19th 2025

Join this expert panel to discuss precision medicine in NSCLC, current immunotherapies, and more.

Watch the series now!

Join a panel of leaders as they discuss treatment for patients diagnosed with metastatic NSCLC without driver mutations
Continuing Medical Education
View All
June 30th 2025

The Economics of Transthyretin-Mediated Amyloidosis: Balancing Equity and Access in Resource Allocation

1 Credit / Cardiology, Neurology
June 30th 2025

Advancing Immunotherapy in Endometrial Cancer: A Managed Care Perspective on Personalized Care

1.5 Credits / Gynecologic Cancer, Health Equity, Diversity & Inclusion, Oncology, Women's Health

More News

FDA | Image Credit: wladimir1804-stock.adobe.com
July 28th 2024

ODAC Votes to Require Trial Assessment of Neoadjuvant vs Adjuvant Benefits in Resectable NSCLC

Caroline Seymour
Should the FDA require that new trial design proposals for perioperative regimens for resectable non–small cell lung cancer (NSCLC) include adequate within trial assessment?
Crystal S. Denlinger, MD, FACP, CEO of the National Comprehensive Cancer Network
July 28th 2024

Addressing Drug Shortages: Enhancing Buffer Stock, Transparency to Mitigate Future Crises

Pearl Steinzor
Crystal S. Denlinger, MD, FACP, CEO of the National Comprehensive Cancer Network, discusses possible federal policies to help mitigate ongoing and future cancer drug shortages.
Female patient holding up breast cancer awareness ribbon | Image Credit: Pixel-Shot - stock.adobe.com
July 27th 2024

Study: Breast Cancer Immunotherapy Trials Make Modest Clinical Impact

Brooke McCormick
Despite numerous trials, breast cancer immunotherapies have had a modest clinical impact, with only 2 approved drugs, highlighting inefficiencies in the clinical trial system.
AI models can be useful tools for clinicians, helping assess risk in patients with HCC to inform disease management. | Image credit: ipopba - stock.adobe.com
July 26th 2024

AI Model Precisely Identifies HCC Recurrence Risk Factors

Rose McNulty
Artificial intelligence (AI) models have potential to help clinicians assess risk in patients with hepatocellular carcinoma (HCC) to inform disease management, a new study found.
Crystal S. Denlinger, MD, FACP, CEO of the National Comprehensive Cancer Network
July 25th 2024

Effective Solutions for Drug Shortages: Market Incentives, Infrastructure, and Quality Management

Pearl Steinzor
Crystal S. Denlinger, MD, FACP, CEO of the National Comprehensive Cancer Network, discusses different policy approaches to address the ongoing cancer drug shortage.
Mammogram screening | Image Credit: okrasiuk - stock.adobe.com
July 25th 2024

Risks, Benefits of Bilateral Mastectomy for Unilateral Breast Cancer

Cameron Santoro
Despite a significant increase in women with unilateral breast cancer who received a bilateral mastectomy, this study found no survival benefit compared with other treatment options. Although removing the unaffected breast reduces the risk of developing cancer in the other breast, results did not show decreased risk of death from breast cancer.
Colon | Image credit: New Africa - stock.adobe.com
July 24th 2024

Metabolic Dysfunction–Associated Steatotic Liver Disease Linked With CRC

Julia Bonavitacola
Patients diagnoesd with metabolic dysfunction–associated steatotic liver disease may have a higher risk of colorectal cancer (CRC) or colorectal adenoma.
dr diane mahoney
July 23rd 2024

Dr Diane Mahoney Uncovers Health Disparities Among Black, Hispanic Ovarian Cancer Survivors

Brooke McCormick
Diane Mahoney, PhD, DNP, FNP-BC, WHNP-BC, APRN, discusses her study on how social determinants of health impact the health perceptions of Black and Hispanic ovarian cancer survivors, highlighting significant health disparities.
Illustration of liver cancer | Image credit: Sebastian Kaulitzki - stock.adobe.com
July 22nd 2024

Response to Immunotherapy Linked With Improved Liver Function in Advanced HCC

Rose McNulty
Although the amount of real-world evidence demonstrating the safety and efficacy of immune checkpoint inhibitors in advanced hepatocellular carcinoma (HCC) has been growing, data on liver function evolution as a prognostic factor for overall survival are lacking.
STS word cloud | Image Credit: Colored Lights-stock.adobe.com
July 16th 2024

Pembrolizumab Promising in Treating Soft Tissue Sarcoma

Maggie L. Shaw
Against the backdrop of a case report, pembrolizumab was investigated as immunotherapy for undifferentiated pleomorphic soft tissue sarcoma.
Jessica K. Paulus, ScD, Ontada
July 13th 2024

Lung Cancer Detection Trends Show Shift in Pandemic Aftermath

Maggie L. Shaw
In this final segment of our interview with Ontada's Jessica K. Paulus, ScD, she explains how her team's data presented at the American Society of Clinical Oncology annual conference may translate to the real world.
Cancer risk infographic | girafchik - stock.adobe.com
July 11th 2024

New Study Reveals 40% of US Cancer Cases, Nearly Half of Deaths Linked to Modifiable Risk Factors

Pearl Steinzor
Cigarette smoking among other modifiable risk factors were significantly associated with cancer cases and deaths.
Prescription drugs illustration | Image credit: Commonwealth Fund
July 9th 2024

FTC Finds PBMs Drive Up Drug Costs, Squeeze Out Competitors

Mary Caffrey
A long-awaited report from the Federal Trade Commission (FTC) finds that vertical integration and consolidation have worked against consumers and independent pharmacies.
Ravin Ratan, MD< MEd, MD Anderson
July 8th 2024

Caring for Patients Is a Team Sport

Maggie L. Shaw
To conclude our interview with him, Ravin Ratan, MD, MEd, of MD Anderson, explains the importance of caring for all patients and why he tries to own the process of patients feeling confident that they received the attention they deserve.
Jessica K. Paulus, ScD, Ontada
Published: July 6th 2024 | Updated: July 1st 2024

COVID-19's Potential Impact on Advanced-Stage Lung Cancer Trends

Maggie L. Shaw
In our ongoing interview with Jessica K. Paulus, ScD, Ontada, she explains potential drivers behind changing trends in care for lung cancer that may have been influenced by the COVID-19 pandemic.
Michael A. Choti, MD, MBA
July 4th 2024

Dr Michael A. Choti: Integrated, Multidisciplinary Cancer Care Management Crucial for Value-Based Medicine

Kyle Munz
Michael A. Choti, MD, MBA, Banner MD Anderson, cochaired the second annual Advancing Value-Based Oncology Care meeting and shared insights into the goals of this year's event and value-based medicine as a whole.
FDA Approval word blocks | Image credit: Dzmitry - stock.adobe.com
July 3rd 2024

FDA Approves FoundationOne Liquid CDx as a Diagnostic Tool for BRCA-Mutated mCRPC

Alexandra Gerlach
FoundationOne Liquid CDx can be used to identify niraparib and abiraterone acetate eligibility in patients with metastatic castration-resistant prostate cancer (mCRPC).
Crystal S. Denlinger, MD, FACP, CEO of the National Comprehensive Cancer Network (NCCN)
July 3rd 2024

Cancer Drug Shortage: Causes, Trends, and Implications for Clinical Trials

Pearl Steinzor
Crystal S. Denlinger, MD, FACP, CEO of the National Comprehensive Cancer Network, breaks down the causes of the ongoing cancer drug shortage, as well as its impact on clinical trials.
Sindhuja Kadambi, MD, MS
July 3rd 2024

Dr Sindhuja Kadambi: It's Time to Address the Needs of the Aging Oncology Population

Kyle Munz
Sindhuja Kadambi, MD, MS, University of Rochester Medical Center, discussed in detail the unique considerations necessary for oncology care in the aging population.
Combustible cigarettes vs e-cigarettes | Andrey Popov - stock.adobe.com
July 3rd 2024

Vaping and Lung Cancer Screening: Reduced Rates Among Vapers Revealed

Pearl Steinzor
e-Cigarette users may be less likely to undergo lung cancer screening, study reveals.
Group of experts | Image Credit: natali_mis-stock.adobe.com
July 3rd 2024

Experts Call for Improved Management Strategies for Dedifferentiated Liposarcoma

Maggie L. Shaw
Dedifferentiated liposarcoma is a fast-growing and more aggressive type of soft tissue sarcoma that originates as a well-differentiated sarcoma and has a typical diagnosis age of 40 to 60 years.
Matthew Callister, MD
July 2nd 2024

Dr Matthew Callister: Value-Based Oncology Is a Platform for Collaboration

Kyle Munz
Matthew Callister, MD, Banner Health, discusses the advantage of value-based oncology care as a platform for collaboration.
essica K. Paulus, ScD, Ontada
June 28th 2024

Real-World Challenges in Cancer Screening: Understanding Data Sources

Maggie L. Shaw
In part 3 of our interview, Jessica K. Paulus, ScD, Ontada, addresses the importance of understanding data sources and their impact on clinical research.
leukemia word map | Image Credit: dizain-stock.adobe.com
Published: June 28th 2024 | Updated: June 28th 2024

Infection Risk With BTK Inhibitors Low, New CLL Study Finds

Jared Kaltwasser
Only about 1% of patients with chronic lymphocytic leukemia (CLL) developed an invasive fungal infection while on a Bruton’s tyrosine kinase (BTK) inhibitor, investigators found.
Ravi Parikh, MD, MPP, assistant professor of medicine and health policy, Perelman School of Medicine, University of Pennsylvania
June 27th 2024

Evaluating Palliative Care Impact: Insights From Tennessee Oncology's OCM Participation

Mary Caffrey Pearl Steinzor
A study finds limited changes in hospice utilization, highlighting challenges in real-world implementation.
Cancer health care concept-wladimir1804-stock.adobe.com.jpeg
June 26th 2024

NCCN Survey Reveals Best Practices for Managing Cancer Drug Shortage

Pearl Steinzor
The National Comprehensive Cancer Network (NCCN) survey finds 89% of centers continue to report shortages for at least one type of systemic therapy.
representation of targeted treatment | Image Credit: Kiattisak-stock.adobe.com
June 23rd 2024

Preclinical Study Shows Promise of Dual Targeted Treatment Against TNBC

AJMC Contributor
Early findings from a new preclinical study indicate that dual blockade of aurora-A kinase and PD-L1 signaling can inhibit tumor growth in triple-negative breast cancer (TNBC), treatment for which has historically remained limited.
Interview with Jessica K. Paulus, ScD, Ontada
June 22nd 2024

Dr Jessica Paulus: Despite Treatment Advances, Progress in Lung Cancer Will Continue to Take Time

Maggie L. Shaw
“The screening victory there is going to take some more time to show its benefit at the population level,” notes Jessica K. Paulus, ScD. “Some of these things are just going to be reductions in mortality that we have to wait to observe over time.”
Hodgkin lymphoma | Image credit: Dr_Microbe - stock.adobe.com
June 18th 2024

BrECADD Regimen Reaches “Unprecedently High” PFS for Patients With Hodgkin Lymphoma

Laura Joszt, MA
The treatment regimen not only significantly improved progression-free survival (PFS) for patients with advanced stage classic Hodgkin lymphoma but was also better tolerated compared with a 20-year-old regimen being used.
Ravin Ratan, MD, MEd, MD Anderson
June 18th 2024

Treating Sarcomas With Cutting-Edge Immune Checkpoint Blockade

Maggie L. Shaw
In part 3 of an interview, MD Anderson’s Ravin Ratan, MD, MEd, discusses neoadjuvant immune checkpoint blockade for 2 specific types of soft tissue sarcomas.
<1
...
456789101112
...
186>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo